Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride

Inclusion Criteria

• Ages between 18 and 75;
• Weighs between 40 ~ 100 kg, and BMI ≥ 18 kg/m2;
• Must have a clinical diagnosis of CAP
• Chest X-ray and /or CT scan show new or persist/progressive infiltrates
• Patients with PORT/PSI score II, III or IV.
• If female, non-lactating and at no risk or pregnancy (post-menopausal or must use adequate birth control)
• The patient is able to receive an intravenous infusion of the drug .

Exclusion Criteria

• Patients with PORT/PSI score I or VI.
• Severe CAP is present if a patient needs invasive mechanical ventilation or requires vasopressors.
• Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary tuberculosis or infection with other mycobacteria or fungi, known bronchial obstruction, a history of post-obstructive pneumonia, other confounding respiratory diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess, empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory infection (chronic obstructive pulmonary disease [COPD] is not exclusionary)
• Clinically significant conduction or other abnormality on 12-lead ECG, or QTc interval
• Potassium is < 3.5 mmol/L
• Any known disease that seriously affect the immune system
• Active hepatitis or decompensated cirrhosis;
• Have used quinolones or fluoroquinolones within 14 days before enrollment
• Patients who are being or will be on a long-term medication of steroids